Lysophosphatidic acid receptor selective antagonists

A compound of the general structure

• wherein R1 is selected from the group consisting of C8-C22 alkyl, C8-C22 alkenyl, and —(CH2)m—Z—R11;
• wherein m is 0-20;
• Z is selected from the group consisting of C4-C8 cycloalkyl, C5-C8 heterocyclic and C5-C8 aryl;
• R11 is selected from the group consisting of C1-C10 alkyl, C1-C20 alkoxyl, C1-C20 alkylthio, and C1-C20 alkylamino;
• R4 is selected from the group consisting of hydroxy, and
• wherein R32 is selected from the group consisting of O, NH and S;
• X is selected from the group consisting of O, NH, S, CH2, CHOH, CHF, CF2, and
• R30 and R31 are independently selected from the group consisting of C1-C2 alkoxy, hydroxy,
• is a heterocyclic substituent selected from the group consisting of
• wherein L, M, and Q are selected from the group consisting of N, NR15, O, S, CR15, CHR15 and CR15R16;
• R13, R14, R15 and R16 are independently selected from the group consisting of H, halo, C1-C6 alkyl, C1-C6 haloalkyl and C1-C6 alkoxy;
• and
• pharmaceutically acceptable salts thereof.